Amgen (NASDAQ:AMGN) declares $2.38/share quarterly dividend, 5.8% increase from prior dividend of $2.25. Forward yield 3.45% ...

The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...

Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.

Amgen released the long-awaited results from its study of weight loss injection MariTide and the results — while promising — ...

With Amgen’s MariTide results at the lower end of investors’ expectation of 20% to 25% weight loss, the much-anticipated ...

Shares in Amgen fell by double digits Tuesday on results for the company’s MariTide shot, which is viewed as a potential ...

The results shed light on how MariTide may measure up to weight loss injections from Novo Nordisk and Eli Lilly and other ...

A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

Unlike its rivals, which require weekly injections, MariTide offers the potential for monthly or less frequent dosing ...

It is not clear what specifically the new facility will produce, though Amgen could be ramping up its manufacturing capacity ...

Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 ...

The market didn't appreciate Amgen 's ( AMGN 1.00%) latest clinical data update, with the biopharma's shares falling more ...